 | Stem Cell InnovationsICO Stem Cell Innovations focuses on research and development in the field of stem cell science, with the dual purposes of furthering human longevity and expanding access to stem cell treatments through cutting-edge technology. IMPORTANT: By investing in this business you agree to ourDisclaimer. All information including our rating, is provided merely for informational purposes. CryptoTotem does not provide investment advice. |
Overview
|
OpenWhat is Stem Cell Innovations
The Stem Cell Innovations (SCI) team claim that their solution will run on two blockchain platforms. The first platform will be built on Ethereum and will be used only for ERC20 tokens. The second custom blockchain will be developed by the SCI engineers specifically for the healthcare environment. Via the SCI app users will be able to buy cord blood services, purchase medical supplies, acquire synthetic stem cells, etc. The ERC20 SCIA tokens will be used to access and pay for the platform services.
DetailsPre-sales: Sep 17, 2018 - Oct 29, 2018Public sales: Nov 21, 2018 - Jan 17, 2019 Token supply: 240,000,000 Soft cap: 3,000,000USD (fiat) Hard cap: 36,000,000 USD(fiat) LegalCountry limitations: China, Cuba, Iran, Syria, United States, North Korea,Registration country: Gibraltar | Token infoTicker: SCIAType: Utility-token Token price in USD: 1 SCIA = 0.15 USD Accepted currencies: ETH BTC LTC USD EUR Bonus program: Pre-Sale Bonuses: Day 1-7: 60% bonus Day 8-14: 55% bonus Day 15-21: 50% bonus Day 22-28: 45% bonus Day 29-42: 40% bonus Main-Sale Bonuses: Day 43-54: 30% bonus Day 55-69: 25% bonus Day 70-End: 15% bonus Funds allocation: 22% - Marketing & Sales 18% - Infrastructure and Project Management 18% - Team and Advisors 15% - IT Development & R&D 11% - International Expansion and Partnership of Stem Labs 9% - Legal 5% - Reserve 2% - Lobbuing Stem Cell USFDA |
Stem Cell Innovations Roadmap
Establishment of Camden RAD, LLC, a company devoted to stem cell research and development.
Camden RAD, LLC is rebranded as Stem Cell Innovations, and a new company is established, based on blockchain technology.
Advanced research begins to determine market and development opportunities.
Attended Token 2049 conference in Hong Kong.
Attended Stem Cell Summit at the University of California in Los Angeles (UCLA).
Attended CBC conference in San Francisco, CA.
Attended ICO20 Summit in Santa Monica, CA.
Integration of smart contract technology is established.
Company headquarters incorporated in Gibraltar, GB.
Strategic efforts toward development begins.
Interviews with potential medical participants take place.
Whitelist is scheduled to go live.
Token Sale starts.
Token Sale ends and min max caps are assessed.
Distribution of Tokens to participants through ERC20 will commence.
SCI will begin final testing and reporting based on blockchain technology being used.
Creation of a non-identical patient identification factor on Passive Blockchain Node will be initialized.
Demo testing for SCI Application v 1.0 will begin.
Release of the SCI Application v1.1
Enrollment begins for doctors, patients, and stem cell laboratories in the United States
Release of Market Surveillance strategy for further growth
Release SCI Application v2.0
Enrollment begins for professionals, patients, and stem cell laboratories in Middle East and across North Africa.
Announcement of first SCI Lab location and franchise expansion plan.
Announcement of clinical development and research strategy in the stem cell field.
Public announcement regarding SCI achievements to date.
First ever online synthetic stem cell purchase through the SCI Application. Release SCI Application v3.0, fully functional platform for professionals and patients.
Stem Cell Lab Evaluation report per first year of operation and development.
Release SCI earnings and financials report.
Release results of SCI's stem cell research and development to date.
Expansion of SCI stem cell labs and clinics in China, Japan, South Korea, and India.
Begin charging membership fees (payable in Stem Cell Innovations tokens) for professional-facing portion of SCI application.
Begin second phase of SCI stem cell research and development.
Release SCI Application v3.5, including professional-facing component to help practitioners become more involved in the stem cell research space and contribute to the network.
Expansion and acquisition of SCI stem cell labs and clinics in Europe.
Release SCI earnings and financials report for second year operation and development.
Release public update on SCI stem cell research and development.
Stem Cell Lab Evaluation report for second year.
Release SCI Application v4.0 including:
A new platform for medical students, universities, and hospitals to engage with the SCI Application.
Fully Functional EMR Worldwide Enforcing HIPPA and expanding of synthetic stem cell delivery to Latin America.
Project team
Advisors
Social media
